There will be an average drop of almost 20% in the price of 288 medicines from December 1, the Federal Office of Public Health says. Savings of around CHF100 million ($100 million) are expected.
The move comes at a time of debate over the high costs of medicines in Switzerland.
The price reduction, which averages 18.8%, will for example affect Dafalgan (paracetamol), ASS Cardio (aspirin) and children’s oral drops Becetamol. Some medicines will even see a drop in price of up to 30%, with a 50% reductionExternal link for the diuretic Aldactone, a medicine used for high blood pressure.
In a statement on FridayExternal link, the health office said 255 medicines would see no price change because they were “economically sustainable” in Switzerland compared with abroad and with other medicines.
It also took a look at generic medicines, co-marketing medicinesExternal link (same product, different brands) and biosimilars (almost identical copy of original product) and found price reductions could be made in 134 out of 237 cases.
This is the second timeExternal link that the health office has cut the price of medicines, the first time coming at the end of 2017. This has allowed for definite savings in this case of CHF225 million, over 350 medicines, the health office said. This was more than the expected CHF190 million.
Debate
There has been much debate in Switzerland about the cost of medicines. In September the government announced its intention to cap prices for generic drugs as part of a package of measures to reduce rising health costs in Switzerland.
In spring it was revealed that generic drugs cost twice as much in Switzerland as in other parts of Europe. Patented drugs were 9% more expensive, a study found.
Several groups, including the price watchdog, consumer advocates and the umbrella organisation of health insurers, have been calling for years for prices to be reduced.
More
More
What’s being done to bring down high drug costs?
This content was published on
We unravel part of the tangled web of players and factors that influence prices of drugs in the US and Switzerland.
Swiss invention: 90-year anniversary of first T-bar ski lift
This content was published on
On Monday it will be 90 years since the world’s first T-bar ski lift went into service in Davos. This Swiss invention was an instant success.
Iran summons Swiss ambassador over US and Italy arrests
This content was published on
Iran has summoned the Swiss ambassador, who represents US interests, to protest against the arrest in the US and Italy of two Iranians.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Costs of generic drugs and outpatient services targeted
This content was published on
The government wants to cap prices for generic drugs as part of a package of measures to reduce rising health costs in Switzerland.
Swiss campaign to make lifesaving drugs affordable
This content was published on
Swiss authorities must act to make lifesaving drugs more affordable by introducing compulsory licensing, says NGO Public Eye.
Meet the man trying to make Switzerland less expensive
This content was published on
Switzerland has an official price watchdog – someone who fights unfair prices that hurt consumers. Where does he see potential for savings?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.